Homology Medicines Inc (NASDAQ:FIXX) has received an average rating of “Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $30.13.

FIXX has been the subject of a number of research analyst reports. ValuEngine raised shares of Alleghany from a “hold” rating to a “buy” rating in a research report on Friday, April 19th. HC Wainwright set a $4.00 target price on shares of Uranium Energy and gave the stock a “buy” rating in a research report on Tuesday, June 11th. Evercore ISI initiated coverage on shares of Homology Medicines in a research report on Thursday, April 11th. They issued an “outperform” rating and a $29.00 target price for the company. Finally, Zacks Investment Research downgraded shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 16th.

Shares of FIXX traded up $0.34 on Thursday, hitting $19.75. 2,373 shares of the stock traded hands, compared to its average volume of 224,220. The stock has a market cap of $870.10 million, a P/E ratio of -9.95 and a beta of 0.17. The firm has a 50 day simple moving average of $19.43. Homology Medicines has a one year low of $15.07 and a one year high of $31.80.

Homology Medicines (NASDAQ:FIXX) last posted its earnings results on Monday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.11). Homology Medicines had a negative return on equity of 34.90% and a negative net margin of 2,253.08%. The company had revenue of $0.27 million during the quarter, compared to the consensus estimate of $1.00 million. Sell-side analysts predict that Homology Medicines will post -2.32 earnings per share for the current year.

In other news, insider Albert Seymour sold 9,300 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $18.98, for a total transaction of $176,514.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James E. Flynn acquired 533,333 shares of the business’s stock in a transaction dated Friday, April 12th. The shares were acquired at an average cost of $22.50 per share, with a total value of $11,999,992.50. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 678,600 shares of company stock valued at $14,446,534. 33.40% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the company. Rhumbline Advisers lifted its stake in shares of Homology Medicines by 137.1% in the 4th quarter. Rhumbline Advisers now owns 21,260 shares of the company’s stock valued at $475,000 after purchasing an additional 12,294 shares during the period. BlackRock Inc. lifted its stake in shares of Homology Medicines by 134.3% in the 4th quarter. BlackRock Inc. now owns 1,460,449 shares of the company’s stock valued at $32,656,000 after purchasing an additional 837,099 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Homology Medicines by 114.0% in the 4th quarter. Bank of New York Mellon Corp now owns 58,527 shares of the company’s stock valued at $1,308,000 after purchasing an additional 31,180 shares during the period. Citigroup Inc. lifted its stake in shares of Homology Medicines by 53.3% in the 4th quarter. Citigroup Inc. now owns 4,180 shares of the company’s stock valued at $93,000 after purchasing an additional 1,453 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Homology Medicines by 49.6% in the 4th quarter. Northern Trust Corp now owns 181,361 shares of the company’s stock valued at $4,055,000 after purchasing an additional 60,163 shares during the period. 52.87% of the stock is owned by hedge funds and other institutional investors.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Further Reading: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.